📋 Tender Overview
DISEASE
Hepatitis C, HIV and Co-Infection
TYPE
Prevention, Treatment
LEAD GRANTEE
Médecins du Monde
STATUS
Current
TIME FRAME
2023 - 2027
GRANT VALUE
US$ 9,363,092
Solutions
Médecins du Monde will evaluate the value and effectiveness of two promising tools for preventing hepatitis C among people who inject drugs. Working in parallel, the project will embed hepatitis C testing and treatment services within harm reduction programs to make vital services available where they are needed the most.
Community groups will play a key role in the success of this work: the wants and needs of people who inject drugs will guide project design and implementation.
To prevent hepatitis C infections in Armenia, Georgia and Tanzania, this new harm reduction program will be guided by Médecins du Monde and its partners’ core values: care, advocacy, and empowerment. Long-lasting changes will only be achieved if the populations concerned have the power to act on their health.
Both products will be piloted at sites in Egypt, India, Kyrgyzstan, Nigeria, South Africa, Tanzania, Ukraine, and Vietnam. Sites in two additional countries – Armenia and Georgia – will trial low dead space syringes. All ten countries will integrate service delivery within harm reduction programs.
This latest initiative builds on a longstanding commitment from Unitaid to address hepatitis C. Previous support has helped drive down the cost of services, simplify screening and diagnosis, demonstrate effective delivery strategies to reach at-risk populations, and increase awareness.
